-
Accelerating the pathway from drug discovery to patient treatment – pioneering advanced development methodologies for new TB drug regimens.
Read More.. -
Empowering African clinical trial sites through tailored local monitoring programmes.
Read More.. -
Developing limitless collaboration opportunities – academia, enterprises, governments, foundations, patient groups – a unique platform provided through a non-commercial broker!
Read More..
Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics
We are faced with a global pandemic of tuberculosis and new tools to control this disease are needed urgently. We believe that new drugs are central to any control strategy and the fastest route to tuberculosis elimination.
The consortium brings together a group of scientists from more that 14 countries with skills in clinical trials, pulmonology, mycobacteriology, pharmacokinetics, statistics and delivery of clinical service.
Our Scientific Network
MAMS study has completed first interim analysis
PanACEA, the Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics aims to develop TB regimens that significantly shorten treatment duration, funded...
MAMS study sites rapidly enrolling patients
PanACEA’s MAMS study continues to enroll patients rapidly. By mid-October more than 200 of the required 372 patients have been enrolled. Recruitment is thus ahead of...
The 5th Annual PanACEA Meeting
The 5th Annual PanACEA Meeting has been held on Ile de Gorée / Dakar, Senegal from 19-21 Oct 2013, just preceeding the 7th EDCTP Forum. Inspite of a couple of...